Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Ewing 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 4Vincristine 3Temozolomide 3Magnetic Resonance Spectroscopy 3Ifosfamide 3Etoposide 3Doxorubicin 3ulixertinib 2tipifarnib 2selpercatinib 2liposomal doxorubicin 2ivosidenib 2cabozantinib 2X-Rays 2Topotecan 2Specimen Handling 2Radiation 2Phantoms, Imaging 2Nuclear Medicine Department, Hospital 2Irinotecan 2Eflornithine 2Congresses as Topic 2trifluridine tipiracil drug combination 1tazemetostat 1talazoparib 1palbociclib 1olaparib 1larotrectinib 1irinotecan sucrosofate 1ganitumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × etoposide phosphate × 30 days × Clear all
NCT02306161 2026-06-03

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
312 enrolled 14 charts
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡